drugset / Trial / NCT00259116
A Pilot Study of Recombinant Human Relaxin (rhRlx) in Compensated Congestive Heart Failure
Phase 2
Completed
18 enrolled
Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This trial is a single center, open-label, dose-finding study of recombinant human relaxin (rhRlx) given intravenously (IV) to patients with stable, compensated CHF.
Timeline
- Start
- 2005-11
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Relaxin | Protein / enzyme biologic | — | Intravenous |